Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
medline:
30
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
The number of patients with small nonfunctional pancreatic neuroendocrine tumors (NF-PanNETs) is increasing. However, the role of surgery for small NF-PanNETs remains unclear. To evaluate the association between surgical resection for NF-PanNETs measuring 2 cm or smaller and survival. This cohort study used data from the National Cancer Database and included patients with NF-pancreatic neuroendocrine neoplasms who were diagnosed between January 1, 2004, and December 31, 2017. Patients with small NF-PanNETs were divided into 2 groups: group 1a (tumor size, ≤1 cm) and group 1b (tumor size, 1.1-2.0 cm). Patients without information on tumor size, overall survival, and surgical resection were excluded. Data analysis was performed in June 2022. Patients with vs without surgical resection. The primary outcome was overall survival of patients in group 1a or group 1b who underwent surgical resection compared with those who did not, which was evaluated using Kaplan-Meier estimates and multivariable Cox proportional hazards regression models. Interactions between preoperative factors and surgical resection were analyzed with a multivariable Cox proportional hazards regression model. Of the 10 504 patients with localized NF-PanNETs identified, 4641 were analyzed. These patients had a mean (SD) age of 60.5 (12.7) years and included 2338 males (50.4%). The median (IQR) follow-up time was 47.1 (28.2-71.6) months. In total, 1278 patients were in group 1a and 3363 patients were in group 1b. The surgical resection rates were 82.0% in group 1a and 87.0% in group 1b. After adjustment for preoperative factors, surgical resection was associated with longer survival for patients in group 1b (hazard ratio [HR], 0.58; 95% CI, 0.42-0.80; P < .001) but not for patients in group 1a (HR, 0.68; 95% CI, 0.41-1.11; P = .12). In group 1b, interaction analysis found that age of 64 years or younger, absence of comorbidities, treatment at academic institutions, and distal pancreatic tumors were factors associated with increased survival after surgical resection. Findings of this study support an association between surgical resection and increased survival in select patients with NF-PanNETs measuring 1.1 to 2.0 cm who were younger than 65 years, had no comorbidities, received treatment at academic institutions, and had tumors of the distal pancreas. Future investigations of surgical resection for small NF-PanNETs that include the Ki-67 index are warranted to validate these findings.
Identifiants
pubmed: 36976561
pii: 2802815
doi: 10.1001/jamanetworkopen.2023.4096
pmc: PMC10051047
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e234096Références
J Surg Oncol. 2019 Dec;120(7):1071-1079
pubmed: 31571225
Surgery. 2015 Dec;158(6):1556-63
pubmed: 26070847
J Clin Endocrinol Metab. 2013 Dec;98(12):4784-9
pubmed: 24057286
Surgery. 2016 Jan;159(1):302-9
pubmed: 26547726
Scand J Gastroenterol. 2016;51(2):245-52
pubmed: 26513346
JAMA Surg. 2013 Oct;148(10):932-9
pubmed: 23986355
Ann Diagn Pathol. 2015 Apr;19(2):81-7
pubmed: 25702616
Ann Surg Oncol. 2016 Apr;23(4):1361-70
pubmed: 26597365
Neuroendocrinology. 2018;107(4):375-386
pubmed: 30300897
J Natl Compr Canc Netw. 2021 Jul 28;19(7):839-868
pubmed: 34340212
Oncologist. 2022 Jul 5;27(7):573-578
pubmed: 35348774
Scand J Gastroenterol. 2014 Nov;49(11):1367-74
pubmed: 25180490
Adv Med Sci. 2016 Mar;61(1):147-53
pubmed: 26774266
Ann Surg Oncol. 2013 Sep;20(9):2815-21
pubmed: 23771245
Endocr Connect. 2019 Jul;8(7):1052-1060
pubmed: 31252400
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Ann Surg Oncol. 2018 Aug;25(8):2467-2474
pubmed: 29789972
J Gastroenterol. 2021 Nov;56(11):1033-1044
pubmed: 34586495
Dig Endosc. 2020 Nov;32(7):1031-1041
pubmed: 31995848
Pancreas. 2020 Jan;49(1):1-33
pubmed: 31856076
Endoscopy. 2014 Jan;46(1):32-8
pubmed: 24218309
Front Med (Lausanne). 2020 Dec 23;7:598438
pubmed: 33425946
Arch Surg. 2011 May;146(5):534-8
pubmed: 21576607
Ann Surg Oncol. 2008 Mar;15(3):683-90
pubmed: 18183467
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):418-25
pubmed: 24142395
Am J Surg Pathol. 2013 Jun;37(6):853-9
pubmed: 23598967
Ann Surg Oncol. 2014 Oct;21(11):3515-21
pubmed: 24841347
Ann Surg Oncol. 2017 Sep;24(9):2603-2610
pubmed: 28681158
Endosc Ultrasound. 2021 Sep-Oct;10(5):372-380
pubmed: 34677159
HPB (Oxford). 2018 Mar;20(3):251-259
pubmed: 28988702
Pancreas. 2018 Nov/Dec;47(10):1357-1363
pubmed: 30308537